Skip to main content

Advertisement

Table 4 Variables included in the study

From: Cell-free DNA promoter hypermethylation in plasma as a diagnostic marker for pancreatic adenocarcinoma

  OR 95% CI p value AUC
ALX4 4.29 (1.62; 11.35) 0.0034 0.57
APC 4.16 (2.21; 7.84) 9.67 × 10 −6 0.65
BMP3 7.37 (3.20; 16.95) 2.64 × 10 −6 0.64
BNC1 9.32 (3.90; 22.25) 5.02 × 10 −7 0.65
BRCA1 1.21 (0.49; 2.98) 0.6804 0.51
CDKN2A 2.27 (0.66; 11.17) 0.1652 0.52
CDKN2B 2.42 (0.91; 6.40) 0.0757 0.53
CHFR 0.43 (0.04; 4.19) 0.4668 0.51
ESR1 2.23 (1.22; 4.07) 0.0095 0.58
EYA2 2.30 (0.91; 5.80) 0.0778 0.54
GSTP1 4.01 (0.41; 39.18) 0.2323 0.51
HIC1 3.69 (1.37; 9.91) 0.0097 0.55
MESTv2 2.99 (1.63; 5.49) 0.0004 0.62
MGMT 2.24 (0.52; 9.62) 0.2778 0.51
MLH1 1.48 (0.66; 3.31) 0.3448 0.52
NPTX2 3.37 (1.88; 6.02) 4.34 × 10 −5 0.64
NEUROG1 1.50 (0.59; 3.86) 0.3969 0.52
RARB 1.81 (1.04; 3.15) 0.0348 0.57
RASSF1A 5.28 (2.69; 10.39) 1.4 × 10 −6 0.65
SFRP1 3.30 (1.81; 6.03) 0.0001 0.62
SFRP2 2.00 (1.12; 3.58) 0.0197 0.57
SEPT9v2 6.97 (1.94; 25.03) 0.0029 0.56
SST 3.04 (1.75; 5.30) 8.69 × 10 −5 0.64
TFPI2 12.16 (3.51; 42.04) 7.96 × 10 −5 0.60
TAC1 3.25 (1.86; 5.69) 3.63 × 10 −5 0.64
VIM a
WNT5A 11.31 (1.39; 92.08) 0.0234 0.54
PENK a
Sex 0.85 (0.49; 1.48) 0.5750 0.52
Age 60 3.88 (2.17; 6.92) 4.58 × 106 0.66
Age 65 4.14 (2.33; 7.33) 1.14 × 10 −6 0.67
Age 70 4.05 (2.04; 8.02) 6.06 × 105 0.62
  1. All variables are analysed by simple logistic regression comparing the pancreatic cancer group and control groups 1 + 2
  2. Italic values indicate the genes, where there is significant difference (p < 0.05) in hypermethylation frequency between the cancer group and control groups 1 + 2
  3. a VIM and PENK could not be evaluated by logistic regression because none of the patients in the control group had hypermethylation of the two genes; however, chi-square test found significant difference between the cancer group and the control groups 1 + 2. Despite that, VIM and PENK were excluded from the following analysis because only few cancer patients had VIM or PENK hypermethylation
  4. Control group 1; patients screened but negative for upper gastrointestinal malignancy
  5. Control group 3; patients with chronic pancreatitis
  6. OR odds ratio, CI confidential interval, AUC area under the receiver operating characteristic curve